Effectiveness and Tolerance of Effaclar Serum in Women With Mandibular Acne

Acne Vulgaris Clinical Trial

Official title:

Evaluation of the Effectiveness and Tolerance of Effaclar Ultra Concentrated Serum in Women With Mandibular Acne for 3 Months (Including 2 Months of Treatment)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05457621
• Other study ID #: LRP19011-EFFACLAR SERUM
• Status: Completed
• Phase: N/A
• Start date: January 21, 2021
• Est. completion date: July 8, 2021

Study information

• Verified date: July 2022
• Source: Cosmetique Active International
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The role of "dermocosmetics" in acne management is increasingly important, as many patients and even physicians now resort to them as first-line management in mild-to-moderate acne.

The aim of the study is to demonstrate the efficacy of the tested product on the appearance of acne lesions in 30 adult women suffering from acne in the mandible following an active anti-acne therapy (systemic or topical). This study includes 2 months of cosmetic treatment with EFFACLAR Ultra Concentrated Serum and one month of followup without any treatment but a moisturizer with a daily UV protection.

The investigational product has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance.

This product is expected:

• to leave the skin clean and smooth,

• to help unblock pores,

• to exfoliate dead skin cells and help the skin to appear smoother, softer and pore-less,

• to be non-comedogenic.

Description:

The study is performed in the Centre de Pharmacologie Clinique Appliqué à la Dermatologie (CPCAD), authorized by the French Regional Agency of Health (ARS) to perform biomedical research (Site agreement n°: 2016-04).

This clinical trial protocol and all amendments will be reviewed and approved by an appropriate Independent Ethics Committee (IEC) (Comité de Protection des Personnes (CPP)) located in France. The clinical trial cannot start before CPP approval.

The clinical trial is conducted under the sponsorship of Sponsor in compliance with the applicable international and local regulatory requirements as well as applicable International Council on Harmonisation (ICH) guidelines and in accordance with the Standard Operating Procedures (SOPs) for clinical trial conduct and monitoring from the assigned monitor.

All statistical tests will be two-sided and at the 5% level of significance. Normality tests will be at the 1% level of significance (Shapiro-Wilk).

Regarding the analysis of efficacy endpoints, quantitative parameters are analyzed using a linear mixed model for repeated measurements with Baseline and Time as fixed effects and Subject as random effect. Each time-point is compared to Baseline using a Dunes adjustment for multiplicity correction. For each fitted model, residual plots will be used to check the model assumptions. If there is an obvious deviation to these assumptions, the analysis is done on the rank-transformed data. Ordinal parameters (GEA) are analyzed using a cumulative link mixed model for repeated measurements with Baseline and Time as fixed effects and Subject as random effect. Each time-point will be compared to Baseline using a Dunnett adjustment for multiplicity correction.

The analysis of cosmeticity/acceptability questionnaire is descriptive only and for the analysis of safety endpoints, no statistical analysis is performed on safety. The data are presented descriptively.

As for the sample size determination, a total of 30 subjects completing the whole study allows to answer to the study objectives.

Clinical Research Associates (CRAs) and other applicable personnel are trained prior to study initiation to familiarize CRAs with the disease, the Standard Operating Procedures (SOP), the protocol and other study specific items.

Regarding the data management, the study data will be collected on an electronic data capture (EDC) set up by the Contract Research Organization (CRO). Computerized edit checks and review processes will be performed on an ongoing basis until all data clarifications are resolved. The data will be exported from a special database to be stored in appropriate format. After all data clarifications are resolved, coding is approved, and subject's evaluability is determined, the database will be locked.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 8, 2021
• Est. primary completion date: July 8, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• female subjects aged 20 years or above

• phototype II to IV

• mandibular acne (with or without diffuse acne)

• at baseline (Day0) a AFAST (Adult Female Acne Scoring Tool) score of 1 or 2 in the mandibular area and not over

• 15 non-inflammatory lesions and 5 inflammatory lesions minimum (screening and baseline)

• microcomedones on the mandibular area (visible with Vivacube measurement),

Exclusion Criteria:

• men

• female subject pregnant or lactating or who intends to conceive a child during the clinical trial or within one month after the last clinical trial visit

• facial acne without mandibular acne

• still undergoing medical treatment for acne at baseline (D0)

• intensively exposed to UV within the month preceding the baseline visit

• history of any severe disease or current condition (based on subject's interview and/or results of screening physical examination) which, in the opinion of the Investigator would put the subject at risk by participating in the study or would interfere significantly with the evaluation of study results (e.g. cancer, immune disorders)

Related Conditions & MeSH terms

• Acne Vulgaris

Intervention

Other:
• Effaclar serum
Effaclar serum has been formulated with an ultra-concentrated tri-acids complex for a synergetic action on skin and reinforced with soothing niacinamide for optimal tolerance. It acts in particular on imperfections and persistent marks due to acne.

Locations

Country	Name	City	State
France	Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD)	Nice

Sponsors (1)

Lead Sponsor	Collaborator
Cosmetique Active International

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in GEA (Global Evaluation Acne) score	evaluation of the acne grade by the investigator on a 6-point scale (from 0 Clear. No lesions to 5 Very severe)	from baseline to Day84
Primary	change in Adult Female Acne Scoring Tool (AFAST) score	evaluation of the acne grade by the investigator on a 4-point scale	from baseline to Day84
Primary	change in acne count	lesion count by the investigator: inflammatory lesions (papules, pustules, nodules) and non-inflammatory lesions (opened/closed comedones) on full face	from baseline to Day84
Primary	change in the seborrhea evaluation	assessment performed by the investigator by visual inspection (gloss and shine aspect), and recorded using a 0-3 grading scale	from baseline to Day84
Secondary	change in subject's and Investigator's global assessment of efficacy	opinion given on the global efficacy of the study treatment at each visit (except Day0), using a 7-point scale	from Day7 to Day84
Secondary	change in the quantity of sebum	evaluation, with a Sebumeter, of the quantity of sebum excreted to the skin surface. Measurements will be done about 12 h after the last application of any product and 3 h minimum after the last washing of the skin at controlled room temperature (21-25 °C).	from baseline to Day84
Secondary	change in the quality of life	Cardiff Acne Disability Index (CADI) questionnaire with 5 questions	Day0, Day14, Day28, Day56, Day84
Secondary	change in the global tolerance	evaluation of the tolerance both by the investigator and the patient on a 5-point scale (from 0 None to 4 Very severe)	from Day7 to Day84
Secondary	change in the sensitivity assessment by the investigator	assessment of the following signs: erythema, dryness, desquamation by the investigator on a 0-3 score	from Day48 hours (phone call) to Day84
Secondary	change in the sensitivity assessment by the participant	assessment of the following symptoms: itching, tingling, burning sensation by the patient on a 0-3 score	from Day48 hours (phone call) to Day84